Company focused on the research and development of mitochondria based therapeutics.
Our company is a first mover and leader in exploring the mitochondrial genome for therapeutically relevant peptides that have the potential to be developed into transformative and commercially successful drugs. These peptides have been conserved by evolutionary biology due to their important roles in sensing and regulating critical biological functions, far beyond the energy production most frequently associated with mitochondria. Our team has discovered more than 100 mitochondrial derived peptides (MDPs) and generated over 1,000 analogs.
Visit website: https://www.cohbar.com/
CohBar is also referenced in the following:
People at CohBar
Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021
Longevity Technology - 25-Feb-2022
Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.Read more...
Liver-fat content and bodyweight reduction with effective use of CB4211
GlobeNewswire - 10-Aug-2021
Mitochondrial genome used to potentially treat fatty liver and prevent obesityRead more...
CohBar's lead candidate may initiate clinical trials in 2022
Longevity Technology - 16-Mar-2021
Mitochondrial-based therapy enters IND to tackle IPF and other fibrotic diseasesRead more...
From cryonic baths to ozone saunas, to the search of magic pill
Wired - 10-Sep-2019
In 2018 consumers spent $43 billion on anti-ageing products according to Orbis analysisRead more...